Skip to main content
Peter O'Donnell, MD, Oncology, Chicago, IL

PeterHughO'DonnellMD

Oncology Chicago, IL

Genitourinary Oncology, Hematologic Oncology

Assistant Professor of Medicine, University of Chicago, Pritzker School of Medicine

Dr. O'Donnell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. O'Donnell's full profile

Already have an account?

  • Office

    5841 S Maryland Ave
    # MC2115
    Chicago, IL 60637
    Phone+1 773-702-4400
    Fax+1 773-702-3163

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Hematology and Medical Oncology, 2006 - 2010
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 2004 - 2006
  • University of North Carolina Hospitals
    University of North Carolina HospitalsResidency, Internal Medicine, 2003 - 2004
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2003

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2004 - 2026
  • NC State Medical License
    NC State Medical License 2003 - 2004
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)— Updated response and survival results. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in Cancer
    ASCO Annual Meeting Returns to Chicago, Celebrates New Progress in CancerJune 15th, 2022
  • UTSW Finds Potential Key to Predict Immunotherapy Toxicity
    UTSW Finds Potential Key to Predict Immunotherapy ToxicityAugust 15th, 2023